TY - JOUR
T1 - Evolving BioAssay Ontology (BAO)
T2 - Modularization, integration and applications
AU - Abeyruwan, Saminda
AU - Vempati, Uma D.
AU - Küçük-McGinty, Hande
AU - Visser, Ubbo
AU - Koleti, Amar
AU - Mir, Ahsan
AU - Sakurai, Kunie
AU - Chung, Caty
AU - Bittker, Joshua A.
AU - Clemons, Paul A.
AU - Brudz, Steve
AU - Siripala, Anosha
AU - Morales, Arturo J.
AU - Romacker, Martin
AU - Twomey, David
AU - Bureeva, Svetlana
AU - Lemmon, Vance
AU - Schürer, Stephan C.
N1 - Funding Information:
This work was funded by the National Institutes of Health (NIH) National Human Genome Research Institute (RC2-HG005668 and RC2-HG005668-02S1, awarded to SCS and VL), the NIH LINCS program via the National Heart, Lung, and Blood Institute (U01-HL111561 and U01-HL111561-02S1, awarded to SCS), the National Institute of Neurological Disorders and Stroke (R01-NS080145, awarded to VL, Prof John Bixby and SCS ). JAB, PAC, and SB were supported as part of the NIH RoadMap Molecular Libraries Initiative (U54-HG005032, awarded to Prof Stuart L. Schreiber). We also acknowledge resources from the Center of Computational Science of the University of Miami.
Funding Information:
The publication costs for this article were funded by the Center of Computational Science of the University of Miami. This article has been published as part of Journal of Biomedical Semantics Volume 5 Supplement 1, 2014: Proceedings of the Bio-Ontologies Special Interest Group 2013. The full contents of the supplement are available online at http:// www.jbiomedsem.com/supplements/5/S1.
Publisher Copyright:
© 2014 Abeyruwan et al.
PY - 2014
Y1 - 2014
N2 - The lack of established standards to describe and annotate biological assays and screening outcomes in the domain of drug and chemical probe discovery is a severe limitation to utilize public and proprietary drug screening data to their maximum potential. We have created the BioAssay Ontology (BAO) project (http:// bioassayontology.org) to develop common reference metadata terms and definitions required for describing relevant information of low-and high-throughput drug and probe screening assays and results. The main objectives of BAO are to enable effective integration, aggregation, retrieval, and analyses of drug screening data. Since we first released BAO on the BioPortal in 2010 we have considerably expanded and enhanced BAO and we have applied the ontology in several internal and external collaborative projects, for example the BioAssay Research Database (BARD). We describe the evolution of BAO with a design that enables modeling complex assays including profile and panel assays such as those in the Library of Integrated Network-based Cellular Signatures (LINCS). One of the critical questions in evolving BAO is the following: how can we provide a way to efficiently reuse and share among various research projects specific parts of our ontologies without violating the integrity of the ontology and without creating redundancies. This paper provides a comprehensive answer to this question with a description of a methodology for ontology modularization using a layered architecture. Our modularization approach defines several distinct BAO components and separates internal from external modules and domain-level from structural components. This approach facilitates the generation/extraction of derived ontologies (or perspectives) that can suit particular use cases or software applications. We describe the evolution of BAO related to its formal structures, engineering approaches, and content to enable modeling of complex assays and integration with other ontologies and datasets.
AB - The lack of established standards to describe and annotate biological assays and screening outcomes in the domain of drug and chemical probe discovery is a severe limitation to utilize public and proprietary drug screening data to their maximum potential. We have created the BioAssay Ontology (BAO) project (http:// bioassayontology.org) to develop common reference metadata terms and definitions required for describing relevant information of low-and high-throughput drug and probe screening assays and results. The main objectives of BAO are to enable effective integration, aggregation, retrieval, and analyses of drug screening data. Since we first released BAO on the BioPortal in 2010 we have considerably expanded and enhanced BAO and we have applied the ontology in several internal and external collaborative projects, for example the BioAssay Research Database (BARD). We describe the evolution of BAO with a design that enables modeling complex assays including profile and panel assays such as those in the Library of Integrated Network-based Cellular Signatures (LINCS). One of the critical questions in evolving BAO is the following: how can we provide a way to efficiently reuse and share among various research projects specific parts of our ontologies without violating the integrity of the ontology and without creating redundancies. This paper provides a comprehensive answer to this question with a description of a methodology for ontology modularization using a layered architecture. Our modularization approach defines several distinct BAO components and separates internal from external modules and domain-level from structural components. This approach facilitates the generation/extraction of derived ontologies (or perspectives) that can suit particular use cases or software applications. We describe the evolution of BAO related to its formal structures, engineering approaches, and content to enable modeling of complex assays and integration with other ontologies and datasets.
UR - http://www.scopus.com/inward/record.url?scp=84938093882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938093882&partnerID=8YFLogxK
U2 - 10.1186/2041-1480-5-S1-S5
DO - 10.1186/2041-1480-5-S1-S5
M3 - Article
AN - SCOPUS:84938093882
VL - 5
JO - Journal of Biomedical Semantics
JF - Journal of Biomedical Semantics
SN - 2041-1480
M1 - S5
ER -